Published in

Oxford University Press, Clinical Infectious Diseases, 1(75), p. e869-e873, 2022

DOI: 10.1093/cid/ciac201

Links

Tools

Export citation

Search in Google Scholar

Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273– and BNT162b2-Vaccinated Individuals

Journal article published in 2022 by Kathleen M. E. Gallagher, Mark B. Leick, Rebecca C. Larson ORCID, Trisha R. Berger ORCID, Katelin Katsis, Jennifer Y. Yam, Marcela V. Maus ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract COVID-19 breakthrough cases among vaccinated individuals demonstrate the value of measuring long-term immunity to SARS-CoV-2 and its variants. We demonstrate that anti-spike T-cell responses and IgG antibody levels are maintained but decrease over time and are lower in BNT162b2- versus mRNA-1273–vaccinated individuals. T-cell responses to the variants are relatively unaffected.